Table 4. CDX2, TTF1, and GATA-3 Profiles of the Tumors and Chromogranin A, Synaptophysin, and CD56 Staining Status of Neuroendocrine Neoplasms According to Their Origin .
| Tumor Type | CDX2 | TTF1 | GATA-3 | ||
| Cholangiocarcinoma | 13/44 (29.5%) | 0/36 | 2/5 (focal) | ||
| Pancreatic adenocarcinoma | 19/38 (50%) | 0/15 | 1/4 (focal) | ||
| Colon adenocarcinoma | 32/33 (97%) | 0/12 | 0/2 | ||
| Stomach adenocarcinoma | 7/7 | 0/1 | - | ||
| Lung adenocarcinoma | 3/13 | 12/17 (70.6%) | 0/1 | ||
| Breast carcinoma | 0/9 | 0/3 | 25/26 (96.2%) | ||
| Female genital | 1/6 | 0/2 | - | ||
| Tumor Origin of NENs | Chromogranin A | Synaptophysin | CD56 | CDX2 | TTF1 |
| NEN of Respiratory system | 11/19 (57.9%) | 19/22 (86.4%) | 20/21 (95.2%) | 0/2 | 16/25 (64.0%) |
| NEN of GI and PB system | 5/6 | 6/6 | 2/3 | 2/3 | 1/3 |
NEN: Neuroendocrine neoplasm, GI: Gastrointestinal, PB: Pancreatobiliary.